What is the elimination process of bioidentical hormones, such as estrogen (E2) and progesterone (P4), in women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bioidentical hormones, such as estrogen (E2) and progesterone (P4), are typically eliminated from the body within 24-48 hours after discontinuation, with the liver playing a primary role in their metabolism and excretion occurring through urine and feces 1. The elimination process of these hormones can vary depending on the type of hormone and administration method. For instance, estradiol has a half-life of 13-20 hours and is usually cleared within 2-3 days, while progesterone has a shorter half-life of 5-20 minutes with complete elimination occurring within 24 hours 1. Some key factors that can affect the elimination of bioidentical hormones include:

  • Liver function
  • Kidney function
  • Age
  • Body composition
  • Concurrent medications It is essential to consider these factors when discontinuing bioidentical hormones, as they can impact the rate of elimination and the return of menopausal symptoms. For accurate hormone level testing after discontinuation, it is recommended to wait at least 48-72 hours for most delivery methods, but 3-6 months for pellet implants 1. In terms of specific elimination times, topical preparations (creams, gels) may have slightly longer elimination times due to skin absorption, while implanted pellets take the longest to eliminate, with hormones detectable for 3-6 months after insertion. Women discontinuing bioidentical hormones should expect a gradual return of menopausal symptoms within days to weeks as hormone levels decline. It is crucial to note that the use of bioidentical hormones, including custom compounded products, is not recommended due to the lack of data supporting their safety and effectiveness compared to standard hormones 1.

From the Research

Elimination Process of Bioidentical Hormones

The elimination process of bioidentical hormones, such as estrogen (E2) and progesterone (P4), in women is not directly addressed in the provided studies. However, we can look at the general information available on the metabolism and elimination of these hormones:

  • Estrogen (E2) is metabolized in the liver and eliminated through the urine and feces 2.
  • Progesterone (P4) is also metabolized in the liver and eliminated through the urine and feces 2.

Factors Affecting Elimination

Several factors can affect the elimination of bioidentical hormones, including:

  • Dose and route of administration: The dose and route of administration of bioidentical hormones can affect their elimination. For example, transdermal administration may result in slower elimination compared to oral administration 3.
  • Individual variability: Individual variability in liver function, kidney function, and other factors can affect the elimination of bioidentical hormones 2.
  • Age and health status: Age and health status can also affect the elimination of bioidentical hormones. For example, older women or women with liver or kidney disease may have impaired elimination of these hormones 3.

Key Points

Key points to consider regarding the elimination of bioidentical hormones include:

  • Bioidentical hormones are metabolized and eliminated by the liver and kidneys.
  • The dose and route of administration can affect elimination.
  • Individual variability, age, and health status can also affect elimination.
  • There is limited information available on the long-term safety and efficacy of bioidentical hormones, including their elimination 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Bioidentical hormones: an evidence-based review for primary care providers.

The Journal of the American Osteopathic Association, 2011

Research

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017

Research

Bioidentical hormones for women with vasomotor symptoms.

The Cochrane database of systematic reviews, 2016

Research

Bioidentical hormone therapy: clarifying the misconceptions.

Cleveland Clinic journal of medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.